VX-661 saw no safety concerns in the canceled study, a fact that helps the prospect's chances in the other trials. If those prove successful, Vertex could widen its patient pool and open up an extra $485 million in revenue potential, analysts have said. Meanwhile, Vertex is looking to Europe to supplement sales growth in the U.S. Orkambi is close to winning its first reimbursement deal on the continent, Chief Commercial Officer Stuart Arbuckle said during the Tuesday call. Despite a slower-than-expected launch in Germany, Vertex expects to secure reimbursement there in December, Arbuckle said. It's likely to be Orkambi's first contract in the region, but others have progressed to the price-negotiations stage, and he expects Europe to drive "significant revenue growth" next year for Vertex. Vertex's third-quarter loss narrowed to $41.8 million from $95.1 million in last year's third quarter.